Phase III migraine flop sends a small-cap biotech player into a deadly tailspin
A small-cap player looking to cash in quickly on a reformulated drug just got flattened this morning as their one-trick pony got hit by a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
